AMEDISYS INC (AMED) Stock Fundamental Analysis
NASDAQ:AMED - Nasdaq - US0234361089 - Common Stock - Currency: USD
Overall AMED gets a fundamental rating of 5 out of 10. We evaluated AMED against 103 industry peers in the Health Care Providers & Services industry. AMED scores excellent on profitability, but there are some minor concerns on its financial health. AMED has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
AMED had positive earnings in the past year.
AMED had a positive operating cash flow in the past year.
Of the past 5 years AMED 4 years were profitable.
Each year in the past 5 years AMED had a positive operating cash flow.
1.2 Ratios
AMED has a Return On Assets of 4.11%. This is in the better half of the industry: AMED outperforms 73.79% of its industry peers.
AMED has a Return On Equity of 7.49%. This is in the better half of the industry: AMED outperforms 67.96% of its industry peers.
With an excellent Return On Invested Capital value of 10.15%, AMED belongs to the best of the industry, outperforming 81.55% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AMED is in line with the industry average of 9.71%.
The last Return On Invested Capital (10.15%) for AMED is above the 3 year average (9.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 7.49% | ||
| ROIC | 10.15% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
1.3 Margins
With a decent Profit Margin value of 3.79%, AMED is doing good in the industry, outperforming 71.84% of the companies in the same industry.
AMED's Profit Margin has declined in the last couple of years.
The Operating Margin of AMED (9.17%) is better than 79.61% of its industry peers.
In the last couple of years the Operating Margin of AMED has remained more or less at the same level.
With a decent Gross Margin value of 43.37%, AMED is doing good in the industry, outperforming 70.87% of the companies in the same industry.
AMED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.17% | ||
| PM (TTM) | 3.79% | ||
| GM | 43.37% |
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMED is creating some value.
The number of shares outstanding for AMED has been increased compared to 1 year ago.
Compared to 5 years ago, AMED has more shares outstanding
The debt/assets ratio for AMED has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.00 indicates that AMED is not in any danger for bankruptcy at the moment.
AMED has a Altman-Z score of 4.00. This is in the better half of the industry: AMED outperforms 73.79% of its industry peers.
The Debt to FCF ratio of AMED is 1.69, which is an excellent value as it means it would take AMED, only 1.69 years of fcf income to pay off all of its debts.
AMED has a Debt to FCF ratio of 1.69. This is amongst the best in the industry. AMED outperforms 83.50% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that AMED is not too dependend on debt financing.
AMED's Debt to Equity ratio of 0.28 is fine compared to the rest of the industry. AMED outperforms 64.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | 4 |
ROIC/WACC1.18
WACC8.63%
2.3 Liquidity
AMED has a Current Ratio of 1.29. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of AMED (1.29) is worse than 60.19% of its industry peers.
AMED has a Quick Ratio of 1.29. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.29, AMED perfoms like the industry average, outperforming 45.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.86% over the past year.
Measured over the past years, AMED shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.46% on average per year.
Looking at the last year, AMED shows a small growth in Revenue. The Revenue has grown by 5.34% in the last year.
AMED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.73% yearly.
EPS 1Y (TTM)4.86%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%21.36%
Revenue 1Y (TTM)5.34%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.09%
3.2 Future
The Earnings Per Share is expected to grow by 7.37% on average over the next years.
Based on estimates for the next years, AMED will show a small growth in Revenue. The Revenue will grow by 4.80% on average per year.
EPS Next Y12.8%
EPS Next 2Y11.02%
EPS Next 3Y7.37%
EPS Next 5YN/A
Revenue Next Year4.17%
Revenue Next 2Y4.71%
Revenue Next 3Y4.8%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.72 indicates a rather expensive valuation of AMED.
67.96% of the companies in the same industry are more expensive than AMED, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.15, AMED is valued at the same level.
A Price/Forward Earnings ratio of 18.52 indicates a rather expensive valuation of AMED.
AMED's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AMED is cheaper than 65.05% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of AMED to the average of the S&P500 Index (21.60), we can say AMED is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.72 | ||
| Fwd PE | 18.52 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMED indicates a somewhat cheap valuation: AMED is cheaper than 62.14% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, AMED is valued a bit cheaper than 78.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.77 | ||
| EV/EBITDA | 11.84 |
4.3 Compensation for Growth
AMED's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of AMED may justify a higher PE ratio.
PEG (NY)1.7
PEG (5Y)N/A
EPS Next 2Y11.02%
EPS Next 3Y7.37%
5. Dividend
5.1 Amount
No dividends for AMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
98.39
+0.47 (+0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners93.07%
Inst Owner Change-1.69%
Ins Owners1.89%
Ins Owner Change6.08%
Market Cap3.23B
Analysts53.75
Price Target102.85 (4.53%)
Short Float %5.84%
Short Ratio5.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)-10.15%
Max EPS beat(2)12.12%
EPS beat(4)2
Avg EPS beat(4)-1.2%
Min EPS beat(4)-15.99%
Max EPS beat(4)12.12%
EPS beat(8)3
Avg EPS beat(8)-0.55%
EPS beat(12)6
Avg EPS beat(12)2.46%
EPS beat(16)8
Avg EPS beat(16)2.78%
Revenue beat(2)0
Avg Revenue beat(2)-2.12%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)-2.05%
Revenue beat(4)1
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)0.13%
Revenue beat(8)1
Avg Revenue beat(8)-1.99%
Revenue beat(12)1
Avg Revenue beat(12)-2.69%
Revenue beat(16)1
Avg Revenue beat(16)-2.79%
PT rev (1m)0%
PT rev (3m)3.55%
EPS NQ rev (1m)-0.8%
EPS NQ rev (3m)-1.24%
EPS NY rev (1m)0.03%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-0.36%
Revenue NY rev (1m)-0.48%
Revenue NY rev (3m)-0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.72 | ||
| Fwd PE | 18.52 | ||
| P/S | 1.36 | ||
| P/FCF | 14.77 | ||
| P/OCF | 14.38 | ||
| P/B | 2.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.84 |
EPS(TTM)4.53
EY4.6%
EPS(NY)5.31
Fwd EY5.4%
FCF(TTM)6.66
FCFY6.77%
OCF(TTM)6.84
OCFY6.95%
SpS72.26
BVpS36.55
TBVpS-2.88
PEG (NY)1.7
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 7.49% | ||
| ROCE | 12.85% | ||
| ROIC | 10.15% | ||
| ROICexc | 12.2% | ||
| ROICexgc | 151.22% | ||
| OM | 9.17% | ||
| PM (TTM) | 3.79% | ||
| GM | 43.37% | ||
| FCFM | 9.22% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexcg growth 3Y57.65%
ROICexcg growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score7
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 9.64% | ||
| Cap/Sales | 0.25% | ||
| Interest Coverage | 7.77 | ||
| Cash Conversion | 80.59% | ||
| Profit Quality | 243.34% | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | 4 |
F-Score7
WACC8.63%
ROIC/WACC1.18
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.86%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%21.36%
EPS Next Y12.8%
EPS Next 2Y11.02%
EPS Next 3Y7.37%
EPS Next 5YN/A
Revenue 1Y (TTM)5.34%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.09%
Revenue Next Year4.17%
Revenue Next 2Y4.71%
Revenue Next 3Y4.8%
Revenue Next 5YN/A
EBIT growth 1Y18.92%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year18.26%
EBIT Next 3Y9.99%
EBIT Next 5YN/A
FCF growth 1Y112.26%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y102.82%
OCF growth 3Y5.48%
OCF growth 5Y1.88%